Drug intelligence / Profile preview

siKIF22

Development stage
Preclinical
Lead developer
Nanjing Medical University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

siKIF22 is a small interfering RNA (siRNA) designed to silence the expression of Kinesin Family Member 22 (KIF22), also known as Kinesin-like DNA-binding protein (Kid). KIF22 is a member of the kinesin-10 family and acts as a motor protein essential for microtubule stability and chromosome movement during mitosis. In various malignancies, including esophageal squamous cell carcinoma (ESCC), KIF22 is overexpressed and correlates with poor clinical outcomes, lymph node metastasis, and advanced tumor stages. By targeting KIF22 mRNA for degradation, siKIF22 inhibits tumor cell proliferation, migration, and invasion. It also promotes apoptosis and induces cell cycle arrest in the G0/G1 phase by modulating the expression of cell cycle-related proteins (such as p21, p27, cyclin D1, and CDK2) and epithelial-mesenchymal transition (EMT) markers (such as E-cadherin, N-cadherin, and Vimentin). Research indicates that KIF22 is a direct target of miR-122, which negatively regulates its expression.

Other names
KIF22 siRNAKIF-22 siRNAKIF 22 siRNAsmall interfering RNA targeting KIF22si-KIF22#1
02

Targets

KIF22 (Aquaporin-6)

Beyond the preview

Go deeper on siKIF22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siKIF22.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call